Jan, 2021 - By SMI
On 16th December 2020, biotechnology company, Valneva SE, announced plans to commence clinical trial of its COVID-19 vaccine in Britain.
Valneva, a company engaged in the development and commercialization of vaccines for infectious diseases, will initiate trial of its COVID-19 vaccine candidate in the U.K. from 16th December 2020. The government has ordered at least 60 million doses of the vaccine. A spokesperson from the company has stated that the first two phases of the clinical trials of Valnevaâ€™s COVID-19 vaccine will focus on testing the vaccineâ€™s efficacy and ability to fuel an immune response following 3 different dosages. The study will be supported by the National Institute of Health and will be conducted at various sites across the country.
The vaccine developerâ€™s goal is to determine the ideal dose of the drug in the second quarter of 2021, and submit it for approval by autumn next year. This suggests a gap of several months from its original vision to achieve a mid-2021 goal. In addition to an order of 60 million doses, the U.K. can buy 130 million more doses for the period 2022-2035 for 1.4 billion euros which amounts to approximately US$ 1.7 billion. The vaccine developed by Valneva contains the deactivated form of a virus which triggers an immune response in the body but does not prompt any health issues. A similar technique is used in the companyâ€™s existing vaccination indicated for Japanese encephalitis.
Valneva, a biotechnology company based in Nantes, Western France, currently has two inoculations against cholera and Japanese encephalitis. Moreover, the company has a third vaccine in phase 2 of clinical trials indicated against Lyme disease; and another one against the chikungunya virus in phase 3 trials. The company is also in the Paris stock market list and is working towards securing a place in the New York stock exchange listing for 2021.
In search of customized market research solution? We are here to help you. Contact us.